SOURCE: Ablynx

October 19, 2009 02:30 ET


GHENT, BELGIUM--(Marketwire - October 19, 2009) - Ablynx [Euronext Brussels: ABLX], announces that it will present an update of its therapeutic pipeline and its recent advances with its Nanobody® technology platform at Ablynx's R&D Update in Ghent today. The Company will also illustrate the specific advantages of the Nanobody® platform compared with some directly competing technologies.

Ablynx now has over 20 programmes in its therapeutic pipeline including three Nanobodies® in clinical trials. Ablynx initiated its first Phase II study at the beginning of September for its lead programme ALX-0081. Also in September, Ablynx's partner Wyeth Pharmaceuticals initiated a Phase II study with an anti-TNF-alpha Nanobody® to combat inflammatory diseases such as rheumatoid arthritis. Nanobodies® have been generated against over 150 different targets including several complex targets such as chemokines, GPCRs and viruses, which are typically extremely difficult to approach with conventional monoclonal antibodies.

"In the last 12 months we have made important progress in delivering Nanobodies® through alternative routes of administration. We will now be able to apply these delivery routes within our therapeutic programmes. We continue to illustrate the differentiating advantages of our technology over those of our competitors. We are delighted with the progress of our clinical programme and anticipate there will be four Nanobodies® in the clinic by the end of this year, two in Phase II and two in Phase I", said Dr Edwin Moses, CEO and Chairman of Ablynx.

The R&D Review Day presentation will be available on the Company's website as of 4:00 pm CET [10:00 am EST] today -


For more information, please contact:

College Hill Life Sciences - for UK/International media enquiries:
Sue Charles, Justine Lamond, John McIntyre
t:   +44 (0)20 7866 7857
f:   +44 (0)20 7866 7900

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68

Eva-Lotta Allan
Chief Business Officer
t:   +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900

This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Complete version of the press release in English:

Copyright © Hugin AS 2009. All rights reserved.

Contact Information